Claims for Patent: 5,821,057

Summary for Patent: 5,821,057

Title:	Assay for agents that affect cholesterol 7alpha-hydroxylase expression and a characterization of its regulatory elements
Abstract:	DNA regulatory elements that control cholesterol 7.alpha.-hydroxylase (CYP7) expression are disclosed, including a CYP7 minigene that comprises nucleotides downstream from about -371 of the proximal promoter region through about the middle of intron II, inclusive of intron I. This minigene further is stably transfected into a cell line, along with a reporter gene. A method is provided for screening agents that inhibit or stimulate expression of the minigene.
Inventor(s):	Chiang; John Y. L. (Stow, OH), Stroup; Diane (Alliance, OH)
Assignee:	Northeastern Ohio Universities (Rootstown, OH)
Application Number:	08/562,985
Patent Claims:	1. A HepG2 host cell stably transformed with a construct comprising a human regulatory CYP7 minigene from -371 to the Bgl II site in the middle of intron II (SEQ ID NO:5). 2. The stably transformed HepG2 host cell according to claim 1, wherein said construct further comprises a reporter gene. 3. An assay for detecting an agent that inhibits or stimulates CYP7 expression, comprising the steps of: (a) contacting with said agent a host cell according to claim 1 in a medium suitable for CYP7 expression and (b) detecting an inhibition or stimulation of CYP7 expression. 4. The stably transformed HepG2 host cell according to claim 2, wherein said reporter gene is luciferase. 5. The method according to claim 3, wherein said agent is a physiological agent endogenous to a human. 6. The method according to claim 3, wherein said agent is a physiological agent exogenous to a human. 7. A method for determining whether an agent stimulates or inhibits CYP7 gene expression comprising the steps of: (a) contacting the agent with a transfected cell containing a construct, wherein said construct comprises (i) human CYP7 DNA that consists of an isolated regulatory element located within a region from -371 to +24 (SEQ ID NO:5), wherein said element is regulatory with respect to CYP7 expression in the presence of bile acids, and wherein the numbering of said element is measured relative to the transcription start site and (ii) heterologous DNA; and (b) determining CYP7 gene expression in said cell. 8. The method according to claim 7, wherein said regulatory element comprises nucleotides -65 to -54. 9. The method according to claim 7, wherein said regulatory element is selected from a group of bile acids responsive elements consisting of nucleotides -371 to -221; -173 to -129 and -79 to -34. 10. The method according to claim 7, wherein said heterologous DNA is a reporter gene. 11. The method according to claim 9, wherein said bile acids responsive element consists of nucleotides -371 to -221. 12. The method according to claim 9, wherein said bile acids responsive element consists of nucleotides -173 to -129. 13. The method according to claim 9, wherein said bile acids responsive element consists of nucleotides -79 to -34. 14. A human regulatory CYP7 minigene that can be transformed stably into HepG2 cells comprising a region of the human CYP7 gene from -371 to the Bgl II site in the middle of intron II (SEQ ID NO:5), wherein the numbering of said minigene is measured relative to the transcription start site. 15. A method for determining whether an agent stimulates or inhibits CYP7 gene expression comprising the steps of: (a) contacting the agent with a transfected cell containing a construct, wherein said construct comprises (i) human CYP7 DNA that consists of an isolated regulatory element located within a region from -371 to -78 (SEQ ID NO:5), wherein said element is regulatory with respect to CYP7 expression in the presence of bile acids, and wherein the numbering of said element is measured relative to the transcription start site, and (ii) heterologous DNA; and (b) determining CYP7 gene expression in said cell. 16. The method according to claim 15, wherein said bile acids responsive element consists of nucleotides -371 to -221. 17. The method according to claim 15, wherein said bile acids responsive element consists of nucleotides -173 to -129. 18. A HepG2 host cell stably transformed with a construct comprising a human regulatory CYP7 minigene comprising nucleotide sequences from -371 to -78 upstream of nucleotide sequences from -36 to the Bgl II site in the middle of intron II (SEQ ID NO:5), whereby the numbering is relative to the transcription start site of the human CYP7 gene. 19. A HepG2 host cell stably transformed with a construct comprising a human regulatory CYP7 minigene comprising nucleotide sequences from -371 to -221 upstream of nucleotide sequences from -36 to the Bgl II site in the middle of intron II (SEQ ID NO:5), whereby the numbering is relative to the transcription start site of the human CYP7 gene.

Details for Patent 5,821,057

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26